Bronchitol^® is a precision spray‐dried form of mannitol that is delivered to the lungs by a specially designed, portable inhaler.  Bronchitol^® improves lung function and helps to clear mucus from the lungs in patients suffering from cystic fibrosis.  Patients are required to pass a tolerance test prior to being prescribed Bronchitol^® to ensure that they are not hyperresponsive to mannitol.

Bronchitol^® (inhaled mannitol) is commercialized in 14 countries. EffRx has an exclusive license agreement with Pharmaxis Ltd, a listed pharmaceutical research company in Australia, for the registration and commercialization of Bronchitol^®  in Switzerland.

EffRx obtained the Swiss Marketing Authorisation for the treatment of cystic fibrosis (CF) in adults and in children aged 6 years and above as an add‐on to best standards of care.

For more information about Bronchitol^® see www.swissmedicinfo.ch